In this cohort, 79 patients (14.5%) had received a PARPi; the proportion of patients who were treated with PARPi varied between patients with hormone receptor+/HER2- breast cancer (5% in first line, 11% in second line, and 12% in third line) and those with TNBC (18% in first line, 44% in second line, and 36% in third line). This evidence concerns the gene NR4A1 and breast cancer.